Loading...
Loading...
HSTO| Name | Value |
|---|---|
| Revenues | 5.0K |
| Cost of Revenue | 62.0K |
| Gross Profit | -57.0K |
| Operating Expense | 3,530.0K |
| Operating I/L | -3,525.0K |
| Other Income/Expense | -329.0K |
| Interest Income | 0.0K |
| Pretax | -3,854.0K |
| Income Tax Expense | -24.0K |
| Net Income/Loss | -3,854.0K |
Histogen Inc. is a clinical-stage therapeutics company specializing in hypoxia-generated growth factor technology and stem cell-free biologic products. Its product portfolio includes HST-003, a human extracellular matrix for articular cartilage defect treatment; HST-004, a cell conditioned media solution for spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for COVID-19 treatment. Additionally, the company's preclinical product candidates, CTS-2090 and CTS-2096, are selective caspase-1 inhibitors targeting inflammasome activation, with applications in various inflammation-mediated diseases.
